Annual Drug Patent Expirations for RYDAPT
Rydapt is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
Drug patent litigation for RYDAPT.
This drug has fifty-five patent family members in twenty-seven countries.
The generic ingredient in RYDAPT is midostaurin. One supplier is listed for this compound. Additional details are available on the midostaurin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
